Eli Lilly and Company vs Xencor, Inc.: Examining Key Revenue Metrics

Biotech Revenue Battle: Eli Lilly vs. Xencor

__timestampEli Lilly and CompanyXencor, Inc.
Wednesday, January 1, 2014196156000009520000
Thursday, January 1, 20151995870000027762000
Friday, January 1, 20162122210000087520000
Sunday, January 1, 20172287130000035711000
Monday, January 1, 20182149330000040603000
Tuesday, January 1, 201922319500000156700000
Wednesday, January 1, 202024539800000122694000
Friday, January 1, 202128318400000275111000
Saturday, January 1, 202228541400000164579000
Sunday, January 1, 202334124100000168338000
Monday, January 1, 202445042700000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotech Giants: Eli Lilly and Xencor

In the ever-evolving landscape of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Eli Lilly and Company has demonstrated a robust upward trajectory, with its revenue surging by approximately 74% from 2014 to 2023. This growth underscores Eli Lilly's strategic prowess in the pharmaceutical industry, as it continues to innovate and expand its market reach.

Conversely, Xencor, Inc., a smaller player in the biotech arena, has shown a more modest revenue increase of around 1,670% over the same period. While its absolute numbers are dwarfed by Eli Lilly, Xencor's growth rate highlights its potential and the increasing interest in its specialized offerings.

This comparison not only showcases the diverse strategies of these companies but also reflects broader trends in the biotech sector, where innovation and adaptability are key to thriving.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025